Financial Comparison: Integer (NYSE:ITGR) and Biomerica (NASDAQ:BMRA)

Biomerica (NASDAQ:BMRA) and Integer (NYSE:ITGR) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, valuation, profitability, institutional ownership and earnings.

Volatility & Risk

Biomerica has a beta of 0.37, indicating that its share price is 63% less volatile than the S&P 500. Comparatively, Integer has a beta of 0.62, indicating that its share price is 38% less volatile than the S&P 500.

Valuation and Earnings

This table compares Biomerica and Integer”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biomerica	$4.45 million	1.62	-$3.78 million	($1.27)	-1.84
Integer	$1.85 billion	2.32	$102.81 million	$3.66	34.54

Integer has higher revenue and earnings than Biomerica. Biomerica is trading at a lower price-to-earnings ratio than Integer, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Biomerica and Integer’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Biomerica	-84.79%	-97.19%	-61.57%
Integer	6.97%	12.79%	6.48%

Institutional & Insider Ownership

22.3% of Biomerica shares are held by institutional investors. Comparatively, 99.3% of Integer shares are held by institutional investors. 18.0% of Biomerica shares are held by company insiders. Comparatively, 1.1% of Integer shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings for Biomerica and Integer, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biomerica	1	0	0	0	1.00
Integer	0	13	1	0	2.07

Biomerica presently has a consensus target price of $9.00, indicating a potential upside of 284.62%. Integer has a consensus target price of $109.86, indicating a potential downside of 13.10%. Given Biomerica’s higher probable upside, equities analysts plainly believe Biomerica is more favorable than Integer.

Summary

Integer beats Biomerica on 12 of the 14 factors compared between the two stocks.

About Biomerica

Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications; or to measure bacteria, hormones, antibodies, antigens, or other substances which may exist in the human body, stools, or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods IBS, that uses a simple blood sample to identify patient-specific foods which may alleviate irritable bowel syndrome symptoms; and H. Pylori diagnostic test that indicates if a patient is infected with the H. Pylori bacteria. In addition, it develops products to indicate if a person has been infected by COVID-19. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.

About Integer

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures. It also provides cardiac rhythm management products, including implantable pacemakers, implantable cardioverter defibrillators, insertable cardiac monitors, implantable cardiac pacing and defibrillation leads, and heart failure therapies; neuromodulation products, such as implantable spinal cord stimulators; and non-rechargeable batteries, feedthroughs, device enclosures, machined components, and lead components and sub-assemblies. In addition, the company offers rechargeable batteries and chargers; and arthroscopic, laparoscopic, and general surgery devices and components, such as harmonic scalpels, shaver blades, burr shavers, radio frequency probes, biopsy probes, trocars, electrocautery components, wound dressings, GERD treatment components, and phacoemulsification needles. Further, it provides orthopedic products that include instruments used in hip, knee, and spine surgeries, as well as reamers and chisels. Additionally, the company offers customized battery power and power management systems, and battery solutions for the energy, military, and environmental markets. Furthermore, the company provides medical technologies. It serves multi-national original equipment manufacturers and their affiliated subsidiaries in the cardiac rhythm management, neuromodulation, orthopedics, vascular, and advanced surgical and portable medical markets. Integer Holdings Corporation was founded in 1970 and is headquartered in Plano, Texas.